Startups · AI

VP of Commercial Strategy & Partnerships

Multiply Labs · San Francisco · On-site

← All jobs
About Multiply Labs

Backed by Y Combinator and Lux.

About the role

We are seeking a hands-on VP of Commercial Strategy & Partnerships to own how Multiply Labs wins, structures, and grows its relationships with global pharmaceutical customers and technology partners. You will build the commercial strategy for our automated advanced biologics manufacturing platform, close complex enterprise agreements, and scale our commercial footprint with pharmaceutical and biotechnology companies. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • 10+ years of commercial leadership experience in business development, enterprise sales, or strategic account management, with 5+ years in the pharmaceutical, biotech, or life sciences sectors
  • Proven track record closing multi-million-dollar, multi-year enterprise agreements with large pharmaceutical companies, including capital equipment, technology platforms, or manufacturing services
  • Experience structuring complex deals: pilots, development agreements, milestone-based payments, capacity or reservation models, and transitions from pilot to commercial scale
  • Skilled negotiator, comfortable owning commercial terms and working closely with legal counsel through contract execution
  • 3+ years managing, mentoring, or developing high-performing customer-facing teams
  • Technical fluency: Bachelor’s in Bioengineering, Molecular Biology, Biochemistry, Engineering, or a related discipline. Ability to converse fluently with biopharma VP/C-level executives in both technical process development and commercial terms
More about this role

Multiply Labs is a robotics company on a mission to solve a significant bottleneck in modern medicine: the manufacturing of life-saving advanced biologics, from gene and cell therapies to antibodies and more.

Today, these therapies are produced through manual, labor-intensive processes. Costs are extremely high—often $500K–$2M per patient—limiting access to only a small fraction of those who need them.

As product complexity increases and the cost of failure and scientific labor rises, the industry is shifting toward automation. Robotics and AI are making automated biologics manufacturing feasible, reliable, and economically scalable.

We believe the future of biomanufacturing is robotic—closed, automated, and scalable—ensuring critical therapeutics are accessible to every patient who needs them.

We don’t just build robots—we’re building the essential infrastructure for next generation biologics. Our technology enables biopharma companies to scale production without redesigning their science, reducing regulatory hurdles and lowering costs so these treatments can reach more patients.

The Mission: Build the world’s best robots to make life-saving therapies accessible to all.

The...

Read the full posting on Multiply Labs's site ↗

Commercial Strategy & Partnerships

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.